Thermo Fisher Scientific (TMO) Equity Ratio (2009 - 2026)

Thermo Fisher Scientific has disclosed Equity Ratio across 18 years of filings, most recently posting 0.46 for Q1 2026.

• Quarterly Equity Ratio fell 8.01% year-over-year to 0.46 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.46 (down 8.01% YoY) and the FY2025 annual result came in at 0.48, down 4.92% from the prior year.
• Equity Ratio declined to 0.46 in Q1 2026, from 0.48 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.51 in Q4 2024 and troughed at 0.44 in Q2 2022.
• A 5-year average of 0.48 and a median of 0.47 in 2023 frame the typical range for Equity Ratio.
• Annual changes were most pronounced in 2022 — Equity Ratio dropped 16.85% — and 2024, when it climbed 7.58%.
• Tracing TMO's Equity Ratio over 5 years: stood at 0.45 in 2022, then gained by 4.42% to 0.47 in 2023, then grew by 7.58% to 0.51 in 2024, then slipped by 4.92% to 0.48 in 2025, then declined by 5.29% to 0.46 in 2026.
• Business Quant data shows TMO's Equity Ratio at 0.46 in Q1 2026, 0.48 in Q4 2025, and 0.5 in Q3 2025.